Abiopharma

Johnson & Johnson - RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Integer Holdings Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Integer Holdings Corporation - ITGR

VR Announces Further Upsize of Brokered Private Placement Led by Centurion One Capital to $2,750,000

Summit Plc - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

RecycLiCo Grants Stock Options